Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients

Simpson, W. J.; Panzarella, Tony; Carruthers, John S.; Gospodarowicz, Mary K.; Sutcliffe, Simon

doi:10.1016/0360-3016(88)90381-1

Cited by 281 publications

(158 citation statements)

References 15 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…Both thyroid profiles for each patient were analyzed by the same laboratory in order to minimize interassay variation. In addition, an aliquot of each blood sample was analyzed in the GCRC Bioanalytic Core Laboratory for TT 3 4 and TT 3 levels were measured by the clinical laboratories using chemiluminescent immunoassays also. Over the period of this study reference ranges were approximately 0.8-1.80 ng=dL for FT 4 and 80-200 ng=dL for TT 3 .…”

Section: Thyroid Profilesmentioning

confidence: 99%

See 1 more Smart Citation

Endogenous Thyrotropin and Triiodothyronine Concentrations in Individuals with Thyroid Cancer

Jonklaas

Nsouli-Maktabi

Soldin

2008

Thyroid

110

102

View full text Add to dashboard Cite

Background: Thyroid hormone suppression therapy is associated with decreased recurrence rates and improved survival in patients with differentiated thyroid cancer. Recently higher baseline thyrotropin (TSH) levels have been found to be associated with a postoperative diagnosis of differentiated thyroid cancer. Our objective was to confirm whether preoperative TSH levels were higher in patients who were diagnosed with differentiated thyroid cancer after undergoing thyroidectomy, compared with patients who were found to have benign disease. We also sought to determine whether thyroid hormone levels were lower in the patients with malignancy. Methods: The study was a retrospective analysis of a prospective study. The study setting was the General Clinical Research Center of an Academic Medical Center. Participants were 50 euthyroid patients undergoing thyroidectomy. Thyroxine, triiodothyronine (T 3 ), and TSH levels were documented in patients prior to their scheduled thyroidectomy. Following thyroidectomy, patients were divided into those with a histologic diagnosis of either differentiated thyroid cancer or benign disease. Preoperative thyroid profiles were correlated with patients' postoperative diagnoses. Results: All patients had a normal serum TSH concentration preoperatively. One-third of the group was diagnosed with thyroid cancer as a result of their thyroidectomy. These patients had a higher serum TSH level (mean ¼ 1.50 mIU=L, CI 1.22-1.78 mIU=L) than patients with benign disease (mean ¼ 1.01 mIU=mL, CI 0.84-1.18 mIU=L). There was a greater risk of having thyroid cancer in patients with TSH levels in the upper three quartiles of TSH values, compared with patients with TSH concentrations in the lowest quartile of TSH values (odd ratio ¼ 8.7, CI 2.2-33.7). Patients with a thyroid cancer diagnosis also had lower T 3 concentrations measured by liquid chromatography tandem mass spectrometry (mean ¼ 112.6 ng=dL, CI 103.8-121.4 ng=dL) than did patients with a benign diagnosis (mean 129.9 ng=dL, CI 121.4-138.4 ng=dL). Conclusion: These data confirm that higher TSH concentrations, even within the normal range, are associated with a subsequent diagnosis of thyroid cancer in individuals with thyroid abnormalities. This further supports the hypothesis that TSH stimulates the growth or development of thyroid malignancy during its early or preclinical phase. We also show for the first time that patients with thyroid cancer also have lower T 3 levels than patients with benign disease.

show abstract

Section: Thyroid Profilesmentioning

confidence: 99%

“…Not only can thyroid hormone be used to control the spread of metastatic thyroid cancer (2,3), but it also decreases recurrence rates in thyroid cancer patients, compared with rates in those who do not receive thyroid hormone (1,(3)(4)(5)(6)(7). Furthermore, use of thyroxine improves overall survival in high-risk patients (8).…”

Section: Introductionmentioning

confidence: 99%

Endogenous Thyrotropin and Triiodothyronine Concentrations in Individuals with Thyroid Cancer

Jonklaas

Nsouli-Maktabi

Soldin

2008

Thyroid

110

102

View full text Add to dashboard Cite

show abstract

“…This notion was further supported by a multicenter Canadian trial upon 1578 patients revealed low TR and CSM in patients with residual microscopic disease treated postoperatively with either RAI ablation or external beam radiotherapy or both together than those treated with thyroid hormone alone. While in patients without obvious residual disease, RAI ablation did not significantly improve survival (Simpson et al, 1998). However, National Thyroid Cancer Treatment Cooperative Study Group (NTCTCSG) published data of 4,767 patients with >5 year follow-up in 2010 with a revised conclusion of no significant impact of RAI ablation upon survival of low risk patients (Jonklaas et al, 2010).…”

Section: Remnant Ablation or Not In Low Risk Wdtc?mentioning

confidence: 99%

Controversies about Radioactive Iodine-131 Remnant Ablation in Low Risk Thyroid Cancers: Are We Near A Consensus?

Zaman¹,

Fatima²,

Padhy³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Well differentiated thyroid cancers (WDTC), including papillary (80%) and follicular (10%) types, are the most common endocrine cancers globally. Over the last few decades most the diagnosed cases have fallen into low risk categories. Radioactive iodine-131 (RAI) has an established role in reducing recurrence and improving the survival in high risk patients. In patients with primary tumor size <1 cm, RAI is not recommended by many thyroid societies. However, low risk WDTC has been an arena of major controversies, most importantly the role and dose of adjuvant RAI for remnant ablation to minimize chances of recurrence and improving survival. This review is an attempt to update readers about the previous and existing practice based on results of nonrandomized trials and evolving trends fueled by recently published randomized studies.

show abstract

“…Se, no rastreamento pós-operatório, são demonstrados restos de tireóide*, e predominante a prescrição de dose ablativa*, na faixa de 30 a 150 mCi, seguida de tratamento supressivo* (2-6). Entretanto, se dose terapêutica* é indicação unânime (2,(7)(8)(9), alguns julgam com ceticismo a dose ablativa (9)(10)(11). Esta tem por fim evitar competição pelo 131 I, visto ser o tumor menos ávido pelo iodo (12).…”

Section: Introdução E Históricounclassified

Dietas com restrição de Iodo (DRI)

Wolff

1998

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

In the context of differentiated thyroid cancer management with radioiodine, a gradual description of low iodine diets (LIDs) is undertaken. A more ample and autoexplicit one is reported, as well as the mechanisms of uptake increase, based on iodine depletion. The efficiency of LIDs in favoring iodine depletion and scanning, as potentially useful for 131 I ablation, but unsettled for 131 I treatment, is examined under the distress of wanting research on the subject. The usefulness of urinary iodine assay to avoid contamination, to appraise adherence to, and efficiency of LIDs, is stressed. In face of increased intake of iodine in the USA, UK and Pacific regions, it is to regret the scarce LID adoption in reports, whose credibility stands only on the belief of tacit informal LID prescription, rarely inserted in "Material and Methods". It is disapproved too the increase in 131 I dose, in case of contamination, since quick depletion of iodine by LID is harmless and efficient. As there is an endemic deficiency of iodine in some regions, it is to doubt the need of LID in Brazil, where no one has been published. Nevertheless, as neither the iodine content of foods, nor the existence of fortuitous excess in some foods are known, the author dares to suggest the

show abstract

Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients

Cited by 281 publications

References 15 publications

Endogenous Thyrotropin and Triiodothyronine Concentrations in Individuals with Thyroid Cancer

Endogenous Thyrotropin and Triiodothyronine Concentrations in Individuals with Thyroid Cancer

Controversies about Radioactive Iodine-131 Remnant Ablation in Low Risk Thyroid Cancers: Are We Near A Consensus?

Dietas com restrição de Iodo (DRI)

Contact Info

Product

Resources

About